Status:
TERMINATED
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this prospective, observational, post-marketing study is to evaluate the patient characteristics, pre-treatment and treatment duration in Renal Cell Carcinoma (RCC) patients w...
Eligibility Criteria
Inclusion
- Patients with diagnosis of advanced Renal Cell Carcinoma (RCC) and decision taken by the investigator to prescribe Nexavar® under Taiwan reimbursement guideline
- Patients must have a life expectancy of at least 8 weeks
Exclusion
- Exclusion criteria must follow the approved local product information.
- Patients were lost to follow-up if no follow-up visit and no final assessment of Nexavar® was documented.
Key Trial Info
Start Date :
December 13 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2012
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01195649
Start Date
December 13 2010
End Date
August 31 2012
Last Update
June 4 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.